Schizophrenia:

Rc, Bland; Sc, N; Orn, Helene

doi:10.1111/j.1600-0447.1987.tb02806.x

Cited by 121 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the magnitude of depression in the current study is lower than the reported magnitude in the USA 50% [27], China 54.6% [5], and in Poland 61% [8]. Contrarily the current prevalence is lower than the estimated magnitude of depression in Canada which was 7.3% [9]. Several factors contributed to these wide number of variations in the magnitude of depression among schizophrenic patients across the studies, including: (1) the variations in the instruments used measure depression with different psychometric properties across the studies (i.e.…”

Section: Discussioncontrasting

confidence: 67%

The prevalence and associated factors of depression among patients with schizophrenia in Addis Ababa, Ethiopia, cross-sectional study

Fanta¹,

Bekele

Ayano³

2020

BMC Psychiatry

View full text Add to dashboard Cite

BackgroundDepression is common among people with schizophrenia and associated with severe positive and negative symptoms, higher rates of disability, treatment resistance and mortality related to suicide, physical and drug-related causes. However, to our knowledge, no study has been conducted to report the magnitude of depression among people with schizophrenia in Ethiopia. Therefore, this study aimed to determine the prevalence and associated factors of depression among people with schizophrenia.MethodA hospital-based cross-sectional study was conducted among 418 patients with schizophrenia selected by systematic sampling technique. Patient Health Questionnaire 9 (PHQ-9) was used to measure depression among the study participants. To identify the potential contributing factors, we performed binary and multivariable logistic regression analysis adjusting the model for the potential confounding factors. Odds ratios (OR) with the corresponding 95% confidence interval (95%CI)) was determined to evaluate the strength of association.ResultThe prevalence estimate of depression among people with schizophrenia was found to be 18.0% [95% confidence interval: 14.50–22.30]. Our multivariable analysis revealed that current substance use (AOR 2.28, 95%CI (1.27, 4.09), suicide attempt (AOR 5.24, 95%CI (2.56, 10.72), duration of illness between 6 and 10 years (AOR 2.09, 95%CI (1.08, 4.04) and poor quality of life (AOR 3.13, 95%CI (1.79, 5.76) were found to be the factors associated with depression among people with schizophrenia.ConclusionThe current study revealed that comorbid depression was high among people with schizophrenia and associated with current substance use, suicide attempt, and long duration of the illness as well as poor quality of life. Attention needs to be given to address comorbid depression among people with schizophrenia.

show abstract

Section: Discussioncontrasting

confidence: 67%

The prevalence and associated factors of depression among patients with schizophrenia in Addis Ababa, Ethiopia, cross-sectional study

Fanta¹,

Bekele

Ayano³

2020

BMC Psychiatry

View full text Add to dashboard Cite

show abstract

“…Recent studies reported that approximately 8–26% of schizophrenic patients met the DSM-IV criteria for OCD (Eisen et al, 1997; Porto et al, 1997; Poyurovsky et al, 1999, 2001; Bermanzohn et al, 2000; Tibbo et al, 2000; de Haan et al, 2002; Nechmad et al, 2003; Ohta et al, 2003; Byerly et al, 2005). However, other investigators have reported rates up to 59.2% (Bland et al, 1987). A common bias in these estimates of comorbidity lies in the enrollment of patients with OCS and not strictly OCD.…”

Section: Methodsmentioning

confidence: 91%

“…However, the two conditions appear to co-occur more commonly than their lifetime prevalence rates of 1–1.5% and 2–3%, respectively, suggest. Finally, several studies investigating OCD comorbidity reported that 10–60% of schizophrenic patients have OCS (Fenton and McGlashan, 1986; Bland et al, 1987; Berman et al, 1995a, 1998; Lysaker et al, 2000; Okasha et al, 2000; Fabisch et al, 2001; Kayahan et al, 2005). …”

Section: Methodsmentioning

confidence: 99%

Obsessive–Compulsive Disorder Comorbidity: Clinical Assessment and Therapeutic Implications

Pallanti¹,

Grassi²,

Sarrecchia³

et al. 2011

Front. Psychiatry

112

View full text Add to dashboard Cite

Obsessive–compulsive disorder (OCD) is a neuropsychiatric disorder affecting approximately 1–3% of the population. OCD is probably an etiologically heterogeneous condition. Individuals with OCD frequently have additional psychiatric disorders concomitantly or at some time during their lifetime. Recently, some authors proposed an OCD sub-classification based on comorbidity. An important issue in assessing comorbidity is the fact that the non-response to treatment often involves the presence of comorbid conditions. Non-responsive patients are more likely to meet criteria for comorbid axis I or axis II disorders and the presence of a specific comorbid condition could be a distinguishing feature in OCD, with influence on the treatment adequacy and outcome.

show abstract

“…[12] Considering the separate lifetime prevalence rates of the two illnesses [(1%–1.5% for schizophrenia[3] and 2%–3% for obsessive-compulsive disorder (OCD)[4]], it seems that obsessive-compulsive (OC) symptoms and schizophrenia coexist more often than chance. [5]…”

Section: Introductionmentioning

confidence: 99%

Neuroanatomical, Neurochemical, and Neurodevelopmental Basis of Obsessive-Compulsive Symptoms in Schizophrenia

Venkatasubramanian¹,

Rao²,

Behere³

2009

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

The prevalence of the obsessive-compulsive symptoms in schizophrenia (OCSS) appears to be higher than that expected on the basis of comorbidity rates. Review of brain abnormalities in schizophrenia and obsessive-compulsive disorder (OCD) reveals involvement of similar regions namely the frontal lobe, the basal ganglia, the thalamus, and the cerebellum, in both the disorders. Neurodevelopmental etiopathogenesis has been proposed to explain schizophrenia as well as OCD. Significant overlap in neurotransmitter dysfunction (serotonin, glutamate, and dopamine) has been documented between schizophrenia and OCD. The New-onset obsessive-compulsive (OC) symptoms have been reported with the use of atypical antipsychotics in the schizophrenia patients In this background, OCSS is an emerging area of recent interests. This article attempts to review the literature on the neurobiology of OCSS. Neuroimaging, neuropsychological, and neuromotor abnormalities in OCSS discussed in the context of neurodevelopmental etiopathogenesis suggest glutamate abnormalities in OCSS. Atypical antipsychotic induced OCSS points towards the possible roles of glutamate and serotonin. Dopamine may be responsible for the beneficial role of antipsychotics in the treatment of OCD. In summary, we propose that glutamate, serotonin, and dopamine abnormalities may be the probable basis for OCSS.

show abstract

Schizophrenia:

Cited by 121 publications

References 36 publications

The prevalence and associated factors of depression among patients with schizophrenia in Addis Ababa, Ethiopia, cross-sectional study

The prevalence and associated factors of depression among patients with schizophrenia in Addis Ababa, Ethiopia, cross-sectional study

Obsessive–Compulsive Disorder Comorbidity: Clinical Assessment and Therapeutic Implications

Neuroanatomical, Neurochemical, and Neurodevelopmental Basis of Obsessive-Compulsive Symptoms in Schizophrenia

Contact Info

Product

Resources

About